Introduction: Improvement of insulin resistance (IR) as contributor of diabetes remission and prevention is a beneficial effect of BS. We investigated the ability of indices using either basal or stimulated glucose/insulin values to assess changes in IR and insulin sensitivity (IS) in morbid obese (MO) patients.

Methods: We included 339 patients: 27 with diabetes mellitus (DM, age 44±12 yrs, BMI 49±10kg/m²), 91 with impaired fasting glucose or impaired glucose tolerance (IFG/IGT), (age 41±11 yrs, BMI 47± 7kg/m²) and 221 with normal glucose tolerance (NGT, age 38±10 yrs, BMI 46± 7kg/m²). All patients underwent a 75g OGTT, glucose and insulin levels were repeatedly measured. IR and IS indices were calculated.

Results: Remission to NGT occurred in 70.4% of DM and in 97.8% of IFG/IGT. Basal and stimulated indices were equally able to demonstrate changes of glucose metabolism (table1). Before BS, IR was higher in DM for all indices (p<0.001). After BS, there were no differences in AUC glucose (p=0.454), HOMA (p=0.905) and Matsuda (p=0.469) but IFG/IGT patients had a higher AUC insulin (p=0.024) and a lower IGI (p=0.024) compared to DM.

Conclusion: Indices using basal values are equally able to assess changes in glucose metabolism compared to stimulated indices. They represent a tool for simple and valid determination of glucose metabolism in this cohort.


J. Brix: None. A. Tura: None. B. Ludvik: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Novo Nordisk A/S, Sanofi. Research Support; Self; Bayer Healthcare Pharmaceuticals Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation. Speaker’s Bureau; Self; Amgen.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at